| Alcohol or gut microbiota: who is the guilty? M Meroni, M Longo, P Dongiovanni International journal of molecular sciences 20 (18), 4568, 2019 | 191 | 2019 |
| The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies M Meroni, M Longo, P Dongiovanni Nutrients 11 (11), 2642, 2019 | 145 | 2019 |
| miRNA signature in NAFLD: a turning point for a non-invasive diagnosis P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani International journal of molecular sciences 19 (12), 3966, 2018 | 135 | 2018 |
| Genetic and epigenetic modifiers of alcoholic liver disease M Meroni, M Longo, R Rametta, P Dongiovanni International journal of molecular sciences 19 (12), 3857, 2018 | 114 | 2018 |
| Nutrition and genetics in NAFLD: the perfect binomium M Meroni, M Longo, A Rustichelli, P Dongiovanni International Journal of Molecular Sciences 21 (8), 2986, 2020 | 107 | 2020 |
| Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? M Longo, M Meroni, E Paolini, C Macchi, P Dongiovanni Metabolism 117, 154708, 2021 | 90 | 2021 |
| Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes M Meroni, P Dongiovanni, M Longo, F Carli, G Baselli, R Rametta, ... EBioMedicine 52, 2020 | 90 | 2020 |
| TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models M Longo, M Meroni, E Paolini, V Erconi, F Carli, F Fortunato, D Ronchi, ... Cellular and Molecular Gastroenterology and Hepatology 13 (3), 759-788, 2022 | 81 | 2022 |
| MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD M Meroni, M Longo, AL Fracanzani, P Dongiovanni EBioMedicine 57, 2020 | 64 | 2020 |
| PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients P Dongiovanni, M Meroni, G Baselli, RM Mancina, M Ruscica, M Longo, ... Journal of lipid research 60 (6), 1144-1153, 2019 | 59 | 2019 |
| Genetics is of the essence to face NAFLD M Meroni, M Longo, G Tria, P Dongiovanni Biomedicines 9 (10), 1359, 2021 | 49 | 2021 |
| Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC M Longo, E Paolini, M Meroni, P Dongiovanni International journal of molecular sciences 22 (8), 4173, 2021 | 45 | 2021 |
| Low lipoprotein (a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease M Meroni, M Longo, R Lombardi, E Paolini, C Macchi, A Corsini, ... Hepatology Communications 6 (3), 535-549, 2022 | 40 | 2022 |
| mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance M Meroni, M Longo, V Erconi, L Valenti, S Gatti, AL Fracanzani, ... Nutrients 11 (11), 2597, 2019 | 40 | 2019 |
| MAFLD in COVID-19 patients: an insidious enemy P Dongiovanni, M Meroni, M Longo, AL Fracanzani Expert review of gastroenterology & hepatology 14 (10), 867-872, 2020 | 36 | 2020 |
| The rs599839 A> G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients M Meroni, M Longo, E Paolini, A Alisi, L Miele, ER De Caro, G Pisano, ... Cancers 13 (8), 1783, 2021 | 25 | 2021 |
| Genetics, immunity and nutrition boost the switching from NASH to HCC P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani Biomedicines 9 (11), 1524, 2021 | 21 | 2021 |
| The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation N Panera, M Meroni, M Longo, A Crudele, L Valenti, E Bellacchio, L Miele, ... EBioMedicine 65, 2021 | 20 | 2021 |
| Cutting-edge therapies and novel strategies for acute intermittent porphyria: step-by-step towards the solution M Longo, E Paolini, M Meroni, P Dongiovanni Biomedicines 10 (3), 648, 2022 | 14 | 2022 |
| α-Lipoic acid improves hepatic metabolic dysfunctions in acute intermittent porphyria: a proof-of-concept study M Longo, E Paolini, M Meroni, L Duca, I Motta, AL Fracanzani, E Di Pierro, ... Diagnostics 11 (9), 1628, 2021 | 14 | 2021 |